Ken Griffin Kamada LTD Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	SELL	$4.78 - $5.75 $132,406 - $159,275	-27,700 Reduced 54.31%	23,300 $115,000
Q1 2024 May 15, 2024	BUY	$5.58 - $6.42 $79,794 - $91,806	14,300 Added 38.96%	51,000 $286,000
Q4 2023 Feb 14, 2024	BUY	$4.14 - $6.22 $110,123 - $165,452	26,600 Added 263.37%	36,700 $224,000
Q3 2023 Nov 14, 2023	BUY	$4.86 - $5.83 $47,628 - $57,134	9,800 Added 3266.67%	10,100 $53,000
Q2 2023 Aug 14, 2023	BUY	$4.48 - $5.53 $896 - $1,106	200 Added 200.0%	300 $1,000
Q4 2022 Feb 14, 2023	BUY	$3.79 - $4.84 $379 - $484	100 New	100 $0

6.48M

200

Ticker KMDA
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 44,800,500
Market Cap $271M
Description
Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytop...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.